TLR2 signaling regulates T cell exclusion in pancreatic ductal adenocarcinoma.

Read full text
Authors: Jacqueline B. Plesset, Meredith L. Stone, John C. McVey, Heather Coho, Kelly Markowitz, Kayjana S. Coho, Jesse Lee, Anna S. Thickens, Devora Delman, Gregory Lawrence Beatty
Cited by: 1
References: 29

Abstract

Pancreatic ductal adenocarcinoma (PDAC) shows profound resistance to immunotherapy due to its immunosuppressive tumor microenvironment. Here, we studied the relationship between T cell infiltration and innate immune signaling in PDAC, identifying TLR2 as a key regulator of T cell exclusion. TLR2 expression correlated with T cell infiltration in both human and mouse PDAC tumors. Using genetic KO models and adoptive T cell transfer experiments, we found that TLR2 expression in both T cells and non-T cells contributes to T cell exclusion in PDAC. Notably, successful infiltration of adoptively transferred tumor-specific T cells required TLR2 deletion in both the transferred cells and the recipient host. The therapeutic implications of these findings are demonstrated through both genetic deletion and pharmacological inhibition of TLR2 using AAV-mediated and antibody-based approaches in murine models, resulting in decreased tumor growth and extended survival. Collectively, these findings identify TLR2 as a key modulator of T cell trafficking and immune suppression within the PDAC microenvironment, suggesting its potential as a therapeutic target for improving treatment outcomes.

Fields of Study & Subjects

T-cell and B-cell Immunology NF-κB Signaling Pathways Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
JCI Insight
Publisher
American Society for Clinical Investigation
Volume
11
Issue
10
Publication date
31 March 2026
Language
EN